Alvarez & Marsal (A&M) continues to expand its capabilities in the biopharmaceutical and medical technology sector offerings with the appointments of Roland Andersson, Edric Engert and Josh Schiffman as Managing Directors, and Rich Rieger as a Senior Director in the Healthcare Industry Group. These hires strategically build upon A&M’s Pharmaceutical and Biotechnology offering led by, industry notable, Jacques Mulder, Managing Director in A&M’s Healthcare Industry Group.
“Americans spend more than half-a-trillion dollars annually on pharmaceuticals and medical devices,” said Martin McGahan, Managing Director and Co-Head of A&M’s Healthcare Industry Group. “The demand for more and improved treatment options will continue to surge, providing opportunities which require foresight, knowledge and know-how. A&M is dedicated to offering the leadership, action and results that BioPharma, Life Sciences and MedTech organizations need to meet these requirements and thrive in this high-stakes market.”
“The challenges facing the healthcare industry, especially in the BioPharma, Life Sciences and MedTech service lines, continue to proliferate in complexity and scope in an increasingly competitive environment,” said Peter Urbanowicz, Managing Director and Co-Head of A&M’s Healthcare Industry Group. “Boosting our ability to steer healthcare organizations through these evolving challenges to achieve their desired results demonstrates our continued commitment to the market. The decades of executive healthcare experience, that Roland, Edric, Josh and Rich bring to A&M furthers our ability to maximize value for clients.”
Andersson has served as an executive in the Biopharmaceutical, Medical Device and Clinical Research Organization (CRO) sectors. Prior to joining A&M, he led the Commercial partnerships division for the leading CRO PAREXEL for six years. He previously led Accenture's Global Life Science R&D Practice, which resulted in strong growth during his tenure there, and headed Arthur D. Littles healthcare practice.
Engert brings more than 25 years of experience as a pharmaceutical executive and consultant across various healthcare sectors to A&M. He has led strategy work focused on operationalizing and implementing downstream improvements throughout businesses and across functions. Prior to joining A&M, Engert headed the biosimilars business unit at Teva and served as Global Head of Portfolio Management and In-licensing for its generics business unit. He previously served as Global Head of Portfolio Management and In-licensing and VP of Strategy, Portfolio, and API Sourcing at Sandoz.
Schiffman specializes in providing management consulting services to healthcare organizations across the value chain. He focuses on business and product strategy, and digital transformation for pharmaceutical and medical technology companies and their investors. Prior to joining A&M, Schiffman held multiple roles at IBM, including in its Healthcare and Commerce operating units. He previously led a venture-backed technology company, Xtify, and performed key strategic development roles at WebMD.
Rieger is a global healthcare leader who has served as an operations executive in, and consultant to, pharmaceutical, biotech, medical device and diagnostics companies, private equity (PE) and venture capital (VC) firms, hospitals and health systems. Rieger specializes in the development of corporate and business unit strategies, R&D and portfolio solutions, partnering/M&A transactions, manufacturing and operations improvements, marketing/commercialization, pricing and market access, and restructuring initiatives. Prior to joining A&M, Rieger was a Managing Director at the Huron Consulting Group and a Principal at L.E.K. Consulting. He also headed Baxter’s Global Pharmaceuticals and Medical Products business.
“Biopharmaceuticals and medical devices are driving healthcare sector growth as we develop more efficient and effective ways to provide both curative and preventive medical care,” said Mr. Mulder. “Increasing reliance on technology as a healthcare solution requires A&M’s operational bench strength to ensure meaningful results for clients, their patients and their organizations.”